2018 FDA Enforcement Review: Drugs, Biologics And Devices

Law360 (January 28, 2019, 12:30 PM EST) -- While some government agencies appeared to be rolling back regulations and ramping down enforcement efforts in 2018, the U.S. Food and Drug Administration was not among them. The FDA worked closely with partner federal agencies throughout the year, deploying the full array of its enforcement tools — administrative remedies, along with criminal and civil actions — to advance the agency’s public health mission. This year-end lookback reviews FDA enforcement activity around drugs, biologics and devices and assesses the FDA’s top enforcement priorities as we look forward to 2019.[1]

Along with its primary enforcement partner, the U.S. Department of Justice, the FDA...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS